Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha 1-antitrypsin augmentation therapy

R A Sandhaus1

  • 1Swedish Hospital, Denver, CO.

Agents and Actions. Supplements
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Alpha 1-proteinase inhibitor (alpha 1-antitrypsin) is an established treatment for emphysema due to its deficiency. Its safety record is impressive, though newer therapies may emerge.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unique and shared systemic biomarkers for emphysema in Alpha-1 Antitrypsin deficiency and chronic obstructive pulmonary disease.

EBioMedicine·2022
Same author

Development of predictive models for airflow obstruction in alpha-1-antitrypsin deficiency.

American journal of epidemiology·2009
Same author

Heritability of lung function in severe alpha-1 antitrypsin deficiency.

Human heredity·2008
Same author

alpha1-Antitrypsin deficiency . 6: new and emerging treatments for alpha1-antitrypsin deficiency.

Thorax·2004
Same author

alpha(1)-antitrypsin deficiency therapy : pieces of the puzzle.

Chest·2001
Same author

Occupational exposure risks in individuals with PI*Z alpha(1)-antitrypsin deficiency.

American journal of respiratory and critical care medicine·2000
Same journal

Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways.

Agents and actions. Supplements·1998
Same journal

Immunomodulation of Crohn's disease by interleukin-10.

Agents and actions. Supplements·1998
Same journal

Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis.

Agents and actions. Supplements·1998
Same journal

Symposium new drugs for inflammatory, allergic and immunologic disease.

Agents and actions. Supplements·1998
Same journal

The complexity of the B7-CD28/CTLA-4 costimulatory pathway.

Agents and actions. Supplements·1998
Same journal

A role for inflammatory cytokines in the productive activation of antigen-specific CD4+ T-cells.

Agents and actions. Supplements·1998
See all related articles

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Alpha 1-proteinase inhibitor (alpha 1-antitrypsin) is derived from pooled human serum.
  • Intravenous administration of Prolastin has been the accepted treatment for pulmonary emphysema due to alpha 1-antitrypsin deficiency since 1988.

Purpose of the Study:

  • To review the established and experimental uses of alpha 1-proteinase inhibitor.
  • To consider its future role in post-lung transplant therapy for alpha 1-antitrypsin deficient patients.

Main Methods:

  • Review of existing literature and clinical use of Prolastin.
  • Discussion of experimental applications and potential future therapeutic roles.

Main Results:

  • Prolastin is an accepted treatment for emphysema in alpha 1-antitrypsin deficiency.

Related Experiment Videos

  • It has shown success in treating panniculitis and experimental use in cystic fibrosis.
  • Its safety record is impressive.

    • Conclusions:

    • Alpha 1-proteinase inhibitor has a well-established role in treating emphysema.
    • Its utility in cystic fibrosis, panniculitis, and post-transplant care requires further evaluation.
    • Emerging antiproteases may impact its future use and cost-effectiveness.